Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.54 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.54 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60471 | 0.97 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL1826063 | 0.97 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL4057588 | 0.97 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL2386976 | 0.97 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL3695372 | 0.97 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL1117898 | 0.95 | HPGD (0.81) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL3703105 | 0.95 | ALDH1A1 (0.81) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL12714626 | 0.92 | HPGD (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL3706273 | 0.92 | HPGD (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL1309352 | 0.92 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| CN-114315826-A | Pyridopyrimidine compound and application thereof | 西安交通大学 | 2022-04-12 | — | — | CN | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019112269-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | 주식회사 오스코텍 | 2019-06-13 | — | — | WO | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-8178513-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20090306047-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | ALDH1A1 4505/4885HPGD 2404/4885TSHR 1151/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | ALDH1A1 2689/4885HPGD 132/4885TSHR 2661/4885 |
| US-20090306047-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | PRSS1, BCHE, CTSZ | ALDH1A1 4628/4885HPGD 2083/4885TSHR 1633/4885 |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | ALDH1A1 4505/4885HPGD 2404/4885TSHR 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.